Postmenopausal Bleeding: Diagnosis and Management

Definition

Etiology & Differential Diagnosis

Key statistic: ~10% of women with PMB will have a malignancy (endometrial or cervical). Conversely, 90% of women with endometrial cancer present with PMB.

Important Points on Cause

• Endometrial atrophy is the single most common finding — women are typically menopausal for ~10 years; biopsy often yields scant or insufficient tissue
• Tamoxifen use is associated with endometrial polyps and increases malignancy risk; these polyps may not be detected by office biopsy alone
• Uterine leiomyomas should never be accepted as the cause of PMB — a malignant source must be excluded first
• Functional ovarian tumors secreting estrogen can cause endometrial hyperplasia/carcinoma
• Non-genital sources (hematuria, rectal bleeding) must always be excluded by history and exam

Risk Factors for Endometrial Cancer

• Obesity (excess peripheral estrogen conversion)
• Unopposed exogenous estrogen use
• Tamoxifen use
• Diabetes mellitus, hypertension
• Nulliparity, late menopause
• Hereditary syndromes (Lynch syndrome / HNPCC)
• Estrogen-secreting ovarian tumor

Diagnostic Approach

Step 1 — History & Physical Examination

• Characterize bleeding (duration, amount, associated symptoms)
• Medication history — HRT type/regimen, tamoxifen, anticoagulants
• Pelvic examination: inspect vulva, vagina (atrophic changes, lesions), cervix
• Any grossly visible cervical lesion → cervical biopsy directly
• Assess for uterine size, adnexal masses

Step 2 — First-Line Investigations (run in parallel)

Step 3 — Interpreting Endometrial Thickness on TVUS

Important caveat (equity issue): Recent data show the ≤4 mm cutoff has led to underdiagnosis of endometrial cancer in Black patients. Clinical judgment and low threshold for biopsy should apply regardless of ultrasound findings in high-risk populations. — Sabiston Textbook of Surgery

Step 4 — Tissue Sampling Methods

Endometrial polyps are often missed by office biopsy; hysteroscopy is the gold standard for their detection and removal.

Management

1. Atrophic Vaginitis / Endometrial Atrophy

• Topical (vaginal) estrogens: creams, tablets, or rings — systemic absorption is minimal compared to oral routes
• Systemic HRT if broader menopausal symptoms warrant it
• Treat after excluding malignancy

2. HRT-Related Bleeding

• Continuous combined regimen: irregular bleeding for first few months is expected; resolves in most women after 6 months — endometrial cancer risk is low
• Significant change in withdrawal bleeding or breakthrough bleeding → endometrial sampling indicated
• Missed doses of oral HRT can cause spotting; consider non-oral routes for better compliance
• Unopposed estrogen → endometrial hyperplasia risk ×4–8; always add progestogen in women with a uterus

3. Cervical/Endometrial Polyps

• Cervical polyps: easily removed in office
• Endometrial polyps: hysteroscopic polypectomy — up to 5% undergo malignant transformation; risk higher with tamoxifen use, obesity, and age

4. Endometrial Hyperplasia (2015 ACOG/SGO EIN Nomenclature)

5. Endometrial Cancer

• Requires surgical staging: total hysterectomy + bilateral salpingo-oophorectomy + pelvic/para-aortic lymph node assessment
• Multidisciplinary planning for adjuvant radiotherapy/chemotherapy based on stage and grade
• Even with a normal endometrial stripe on TVUS, endometrial sampling should be performed for persistent PMB
• Poor surgical candidates: progestin therapy (oral/parenteral/IUS) with close surveillance

Special Circumstances

Summary Algorithm

PMB
 └→ Full history + pelvic exam + Pap smear
      └→ Visible cervical lesion? → Biopsy directly
      └→ No lesion → TVUS
           ├→ Endometrial thickness ≤ 4 mm
           │    ├→ No risk factors + bleeding stopped → Monitor
           │    └→ Persistent bleeding / high risk → EMB anyway
           └→ Endometrial thickness > 4 mm
                └→ Endometrial biopsy (office)
                     ├→ Adequate tissue → Histopathology → Treat per result
                     └→ Inadequate / persistent bleeding → Hysteroscopy ± D&C

• Berek & Novak's Gynecology, pp. 479–484
• Sabiston Textbook of Surgery, 20th ed., pp. 2794–2795
• Berek & Novak's Gynecology, pp. 2150–2151 (Endometrial Carcinoma chapter)